Erin Walsh, NP
Psychiatric/Mental Health · Media, PANPI 1346810272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 522 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,932, more than ten times the $280 reported in 2021. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 522 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$715
- Alkermes, Inc.$661
- Axsome Therapeutics, Inc.$638
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,87396%
- Education$3784%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 101 | $1,665 |
| Neurocrine Biosciences, Inc. | 73 | $1,112 |
| AbbVie | 77 | $1,058 |
| Teva Pharmaceuticals USA, Inc. | 27 | $715 |
| Alkermes, Inc. | 38 | $661 |
| Axsome Therapeutics, Inc. | 39 | $638 |
| Otsuka America Pharmaceutical, Inc. | 28 | $535 |
| Corium, LLC | 29 | $497 |
| Lundbeck LLC | 20 | $491 |
| Vanda Pharmaceuticals Inc. | 22 | $378 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $349 |
| Bausch Health US, LLC | 7 | $151 |
| Johnson & Johnson | 7 | $148 |
| Almatica Pharma LLC | 6 | $135 |
| Ironshore Pharmaceuticals Inc. | 5 | $117 |
| Merck | 6 | $116 |
| Idorsia Pharmaceuticals US Inc | 5 | $103 |
| Acadia Pharmaceuticals Inc | 1 | $101 |
| Lilly USA, LLC | 5 | $78 |
| Avanir Pharmaceuticals, Inc. | 4 | $67 |
| Boston Scientific | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $19 |
| Neos Therapeutics, LP | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$101
How this compares
$9,251 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $110,927 |
| VraylarCariprazine Hcl | 23 | $36,626 |
| Lurasidone Hcl | 20 | $23,603 |
| Duloxetine Hcl | 31 | $1,264 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 38 | $862 |
| Fluoxetine Hcl | 53 | $789 |
| Aripiprazole | 41 | $765 |
| Mirtazapine | 32 | $765 |
| Quetiapine Fumarate | 56 | $698 |
| Olanzapine | 28 | $682 |
| Trazodone Hcl | 40 | $618 |
| Buspirone Hcl | 17 | $510 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $504 |
| Sertraline Hcl | 77 | $449 |
| Bupropion XlBupropion Hcl | 23 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,112 | $110,92714 claims |
| AbbVieVraylar | $1,058 | $36,62623 claims |
| Lilly USA, LLCOlanzapine | $78 | $68228 claims |
| Almatica Pharma LLCSertraline Hcl | $135 | $44977 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Media
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.